$7.75
0.64% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
BE0974358906
Symbol
NYXH

Nyxoah SA Stock price

$7.75
+1.77 29.60% 1M
-0.21 2.64% 6M
-0.25 3.13% YTD
-0.72 8.50% 1Y
-11.75 60.26% 5Y
-11.75 60.26% 10Y
-11.75 60.26% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.05 0.64%
ISIN
BE0974358906
Symbol
NYXH
Sector

Key metrics

Market capitalization $296.70m
Enterprise Value $249.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 49.83
P/S ratio (TTM) P/S ratio 59.22
P/B ratio (TTM) P/B ratio 2.72
Revenue growth (TTM) Revenue growth -14.94%
Revenue (TTM) Revenue $5.01m
EBIT (operating result TTM) EBIT $-77.24m
Free Cash Flow (TTM) Free Cash Flow $-65.01m
Cash position $72.43m
EPS (TTM) EPS $-2.14
P/E forward negative
P/S forward 21.43
EV/Sales forward 18.03
Short interest 0.46%
Show more

Is Nyxoah SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Nyxoah SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Nyxoah SA forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Nyxoah SA forecast:

Buy
78%
Hold
22%

Financial data from Nyxoah SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
5.01 5.01
15% 15%
100%
- Direct Costs 1.73 1.73
22% 22%
35%
3.29 3.29
10% 10%
66%
- Selling and Administrative Expenses 39 39
59% 59%
768%
- Research and Development Expense 19 19
54% 54%
380%
-74 -74
48% 48%
-1,476%
- Depreciation and Amortization 3.31 3.31
19% 19%
66%
EBIT (Operating Income) EBIT -77 -77
46% 46%
-1,542%
Net Profit -80 -80
61% 61%
-1,599%

In millions USD.

Don't miss a Thing! We will send you all news about Nyxoah SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nyxoah SA Stock News

Neutral
GlobeNewsWire
15 days ago
Nyxoah to Present at the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – May 28, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Hea...
Neutral
Seeking Alpha
29 days ago
Nyxoah SA (NASDAQ:NYXH ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Pearson Dennis - Investor Relations Olivier Taelman - Chief Executive Officer John Landry - Chief Financial Officer Conference Call Participants Jon Block - Stifel Adam Maeder - Piper Sandler Ross Osborn - Cantor Fitzgerald Suraj Kalia - Oppenheimer & Co. David Rescott - Baird Michael Polark -...
Neutral
GlobeNewsWire
29 days ago
REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technol...
More Nyxoah SA News

Company Profile

Nyxoah SA engages in the research and development, manufacture and sale of medical devices. It focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Its lead solution platform is based on the Genio system, a validated, user-centered, neurostimulation therapy for obstructive sleep apnea (OSA). The company was founded by Robert Taub and Adi Mashiach on July 15, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Head office Belgium
CEO Olivier Taelman
Employees 184
Founded 2009
Website www.nyxoah.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today